Evaluation of the Safety and Efficacy of Using Insulin-like Growth Factor-1 in Patients With a Heart Attack
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
When a patient has a heart attack, a blockage occurs in a coronary artery that delivers
oxygen to the heart muscle. The heart muscle may weaken, causing heart failure. The body
naturally makes a protein called insulin-like growth factor-1 (IGF-1) that may protect the
heart muscle cells from dying and may prevent heart failure or lessen the damage that occurs.
IGF-1 is also available as a drug called mecasermin. In this study, heart attack patients
will be given either a dose of mecasermin or a placebo (inactive treatment) after their
coronary artery has been opened by a stent. The purpose of the study will be to evaluate the
safety of the therapy and to test if the therapy will prevent or lessen heart failure by
evaluating a cardiac magnetic resonance imaging (MRI) taken one day and eight weeks after the
heart attack.